01—Abstract
Summary
Summary of the 8-K filed December 3, 2024. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group issued updated 2024 financial guidance and initial 2025 projections ahead of its December 4, 2024 Investor Conference, disclosed under Item 7.01 (Regulation FD) with the full press release attached as Exhibit 99.1.
The company projects 2025 revenues of $450 billion to $455 billiona, GAAP diluted EPS of $28.15 to $28.65, adjusted EPS of $29.50 to $30.00, and cash flows from operations of $32 billion to $33 billion. For 2024, guidance calls for GAAP diluted EPS of $15.50 to $15.75 and adjusted EPS of $27.50 to $27.75. The large gap between the two years' GAAP figures reflects roughly $8.5 billion of South American impacts (including the loss on the Brazil sale and the held-for-sale classification of remaining South American operations) and about $2.0 billion of direct response costs related to the cyberattack, both of which are excluded from adjusted results.
Investors should note that the 2025 GAAP EPS guidance is substantially higher because these 2024 charges are not expected to recur. On an adjusted basis, the midpoint of 2025 guidance ($29.75b) implies roughly 7.7% growth over the 2024 midpoint ($27.63). The filing is a guidance update rather than a full earnings release, and it does not explain the drivers behind the 2025 projections.
The forward-looking statements section lists a broad set of risks, including medical cost management, government program changes, DOJ litigation related to risk adjustment submissions, cyberattacks, and the continuing exit from South America. Investors should review the Investor Conference materials for management's commentary on these assumptions.
02—Key points
Key Highlights
- 2025 outlook: revenues of $450B to $455B, GAAP diluted EPS of $28.15 to $28.65, and adjusted diluted EPS of $29.50 to $30.00.
- 2025 cash flows from operations projected at $32B to $33B.
- 2024 guidance lowered to GAAP diluted EPS of $15.50 to $15.75 and adjusted EPS of $27.50 to $27.75, reflecting large one-time charges.
- Approximately $8.5B (about $9.15 per share) of 2024 South American impacts, including the Brazil sale loss and held-for-sale losses on remaining South American operations, is excluded from adjusted EPS.
- Approximately $2.0B (about $2.15 per share) of cyberattack-related direct response costs is excluded from 2024 adjusted EPS.
- Adjusted EPS excludes only after-tax intangible amortization (about $1.63B pre-tax in 2025, or $1.75 per share), so the adjusted and GAAP 2025 figures differ by a modest amount.
- Investor Conference webcast begins December 4, 2024 at 8:00 a.m. EST, with materials posted at 6:30 a.m. EST.
03—Questions
Frequently Asked Questions
Why is there such a large gap between 2024 GAAP and adjusted EPS?
The gap is driven mainly by roughly $8.5 billion of South American impacts (about $9.15 per share), including the loss on the February 2024 Brazil sale and losses on remaining South American operations classified as held for sale. Direct response costs related to the cyberattack add about $2.0 billion (about $2.15 per share). The company treats both as non-recurring and excludes them from adjusted results.
Why does 2025 GAAP EPS guidance look so much higher than 2024?
The 2024 GAAP figure absorbs the large South American losses and cyberattack costs. The filing projects no comparable items in 2025 (the 2025 reconciliation shows no South American or cyberattack adjustments), so 2025 GAAP EPS guidance of $28.15 to $28.65 compares against 2024 GAAP guidance of $15.50 to $15.75.
How much growth does the adjusted EPS guidance imply?
The 2025 adjusted EPS range of $29.50 to $30.00 has a midpoint of $29.75. Against the 2024 adjusted midpoint of $27.63, that implies growth of roughly 7.7%. This is a calculation from the filing's guidance ranges, not a figure the company states directly.
What does adjusted EPS exclude, and does that change for 2025?
Adjusted EPS excludes after-tax non-cash amortization of acquisition-related intangible assets, which the filing projects at about $1.63 billion pre-tax in 2025 ($1.75 per share before tax effect, $0.40 tax effect). Unlike 2024, the 2025 reconciliation does not include South American or cyberattack adjustments.
Where can investors find more detail on these projections?
The company is streaming its Investor Conference presentation and management Q&A on December 4, 2024, starting at 8:00 a.m. EST, with materials available on its Investor Relations page at www.unitedhealthgroup.com at 6:30 a.m. EST and a replay afterward. The filing itself does not explain the assumptions behind the 2025 projections, so the conference commentary is the main source for that context.
04—Continue